The Biotech Field That Didn't Exist a Decade Ago Just Got Its Biggest Bet Yet

Why Sarcoma? Why Now?

Sarcoma is the kind of cancer that doesn't get a lot of headlines. It accounts for roughly 1% of adult cancers and about 15% of pediatric cancers. It arises from connective tissues (muscles, fat, bones) rather than the organs most people associate with cancer. And treatment options are brutally limited.

The standard playbook for localized sarcoma is surgery, sometimes followed by radiation or chemo. For patients whose cancer has spread, systemic therapies exist, but their effectiveness is, to put it diplomatically, modest. Most clinical trials lump different sarcoma subtypes together rather than studying specific ones, which muddies the data and makes it harder to find what actually works.

That's where Storm sees its opening. STC-15 targets an enzyme called METTL3, an RNA methyltransferase (a protein that sticks chemical tags onto RNA molecules). In sarcomas, METTL3 appears to play a critical role: it helps transformed stem cells differentiate into malignant connective tissue. Block the enzyme, and you can reprogram those cells, triggering cell death and anti-cancer immune responses.

The company's Phase 1 trial reportedly showed durable tumor regression across multiple sarcoma subtypes, which was enough to greenlight the Phase 2 study. The new trial (NCT06975293) is enrolling patients at U.S. sites and focuses on specific subtypes, including leiomyosarcoma (both uterine and non-uterine) and liposarcoma. STC-15 is given as an oral tablet, which is a meaningful quality-of-life advantage over IV infusions for patients who are already dealing with a brutal diagnosis.

The Competition (or Lack Thereof)

Storm occupies a peculiar competitive position: it's racing in a lane that barely has other runners. The company was the first to enter the epitranscriptomics space, and STC-15 was the first RNA-modifying enzyme inhibitor to enter human clinical trials, period.

That said, it's not entirely alone. EPICS Therapeutics has advanced its own METTL3 inhibitor, EP102, into clinical development for solid tumors. Beyond those two, the field is still largely preclinical, with university labs and smaller biotechs working on next-generation compounds and protein degraders.

No METTL3 inhibitor has reached Phase 3 yet. Storm's Phase 2 is designed to potentially support accelerated regulatory approval, which would be a first for the entire epitranscriptomics field. That's a big "if," but it's exactly the kind of bet that gets pharma venture arms excited.

The Bigger Picture

Storm isn't putting all its eggs in the sarcoma basket. The company is also running a separate Phase 1b/2 combination trial exploring STC-15 in other tumor types, including non-small cell lung cancer, head and neck squamous cell carcinoma, melanoma, and endometrial cancer. Preclinical work has shown the drug works synergistically with venetoclax in acute myeloid leukemia models, hinting at future combination strategies in blood cancers too.

The company's broader discovery platform targets the many known RNA-modifying enzymes and more than 150 documented RNA modifications, which represents a massive untapped target space. For context, the entire kinase inhibitor revolution in oncology (think Gleevec and its descendants) was built on a family of about 500 proteins. Storm is eyeing a target class of similar scale that's barely been touched therapeutically.

So What Does This Mean?

For sarcoma patients, any new option with genuine clinical signal is meaningful. The existing treatment landscape is thin, follow-up care is inconsistent (one survey found 32% of survivors reported insufficient follow-up), and most trials haven't been designed with specific subtypes in mind. A targeted oral therapy that showed tumor regression in Phase 1 is, at minimum, a reason for cautious optimism.

For the broader biotech world, Storm's milestones represent a proof of concept for an entire therapeutic field. Epitranscriptomics went from "interesting academic observation" to "funded clinical program with pharma-backed investors" in about a decade. If the Phase 2 delivers, it won't just validate STC-15; it'll validate the idea that RNA modifications are a druggable frontier worth billions in R&D investment.

Storm's CEO Jerry McMahon called the milestone a "pivotal breakthrough." That's CEO-speak, sure. But when your existing investors hand you $56 million without bringing in anyone new, and your drug is the first of its kind to reach Phase 2 in a cancer with almost no good options, the hyperbole might actually be earned this time.

The next chapter depends entirely on what the Phase 2 data shows. For now, though, Storm has done something rare in biotech: it made a field that didn't exist into one that Wall Street is willing to bet on twice.

J&J Spent $415 Million on This Eye Gene Therapy. MeiraGTx Just Bought It Back for $25 Million.

MeiraGTx paid $25 million to buy back a gene therapy that J&J acquired for up to $415 million, after the program's Phase 3 trial missed its primary endpoint. Now the company is racing to file for approval anyway, betting that J&J walked away too soon.